ReviewThe Journal of clinical investigation2016
HIV-specific CD8⁺ T cells and HIV eradication.
Review in The Journal of clinical investigation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Hitchhiker Guide to CD4Frontiers in immunology · 2021Pooled it
- T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020.Frontiers in immunology · 2020Pooled it
- Trial
- Thymosin α1-induced secretion of the IL-15/RA complex by THP-1-derived dendritic cells restrains HIV latencyVirulence · 2026Article
- HIV cure: from early therapies to cutting-edge strategies.Journal of neurovirology · 2026Review
- Recent advances in molecular mechanisms to improve the efficacy of CAR-T cell therapy for viral diseases, cancer, and autoimmune diseases.Stem cell research & therapy · 2026Review
- Renaissance of antiviral CD8Nature reviews. Immunology · 2026Review
- Learning from nature: HIV elite controllers as blueprints for a functional cure.Virology journal · 2025Review
- The tuberculosis-associated microenvironment promotes HIV-1 persistence by impairing CD8+ T cell-mediated viral control.bioRxiv : the preprint server for biology · 2025Article
- Impact on clinical biomarkers, immune recovery, and HIV reservoir dynamics of switching to EVG/c/FTC/TAF versus maintaining a non-INSTI-based regimen in virologically suppressed individuals.Infectious diseases & immunity · 2025Article
- Insights of HIV-1 and HBV transcriptional regulation by viral transactivator Tat and HBx.Virus genes · 2025Review
- EZH2 inhibition mitigates HIV immune evasion, reduces reservoir formation, and promotes skewing of CD8Cell reports · 2025Article
- HIV-related Differences in Placental Immunology: Data From the PRACHITi Cohort in Pune, India.Open forum infectious diseases · 2025Article
- Optimized intravital three-photon imaging of intact mouse tibia links plasma cell motility to functional states.iScience · 2024Article
- Accelerated CD8iScience · 2024Article
- Bryostatin-1 enhances the proliferation and functionality of exhausted CD8+ T cells by upregulating MAP Kinase 11.Frontiers in immunology · 2024Article
- Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeys.NPJ vaccines · 2023Article
- Proviral location affects cognate peptide-induced virus production and immune recognition of HIV-1-infected T cell clones.The Journal of clinical investigation · 2023Article
- Prevention, treatment and cure of HIV infection.Nature reviews. Microbiology · 2023Review
- The latency-reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific T cells.JCI insight · 2023Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
After the success of combination antiretroviral therapy (cART) to treat HIV infection, the next great frontier is to cure infected persons, a formidable challenge. HIV persists in a quiescent state in resting CD4+ T cells, where the replicative enzymes targeted by cART are not active. Although low levels of HIV transcripts are detectable in these resting cells, little to no viral protein is produced, rendering this reservoir difficult to detect by the host CD8+ T cell response. However, recent advances suggest that this state of latency might be pharmacologically reversed, resulting in viral protein expression without the adverse effects of massive cellular activation. Emerging data suggest that with this approach, infected cells will not die of viral cytopathic effects, but might be eliminated if HIV-specific CD8+ T cells can be effectively harnessed. Here, we address the antiviral properties of HIV-specific CD8+ T cells and how these cells might be harnessed to greater effect toward achieving viral eradication or a functional cure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.